Free Trial

Maravai LifeSciences (NASDAQ:MRVI) Stock Price Up 6.1% - Should You Buy?

Maravai LifeSciences logo with Medical background

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s share price traded up 6.1% during trading on Thursday . The company traded as high as $2.31 and last traded at $2.35. 90,810 shares changed hands during trading, a decline of 96% from the average session volume of 2,343,125 shares. The stock had previously closed at $2.21.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Baird R W downgraded Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Bank of America decreased their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Robert W. Baird dropped their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Morgan Stanley cut their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. Finally, Craig Hallum lowered their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $6.64.

Get Our Latest Analysis on Maravai LifeSciences

Maravai LifeSciences Stock Down 5.1%

The stock has a market capitalization of $543.70 million, a price-to-earnings ratio of -1.30 and a beta of 0.19. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The business has a fifty day moving average of $2.06 and a 200 day moving average of $3.70.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $46.85 million during the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The firm's revenue was down 26.9% on a year-over-year basis. As a group, equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current year.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in Maravai LifeSciences in the 1st quarter valued at approximately $429,000. McAdam LLC purchased a new position in shares of Maravai LifeSciences during the first quarter worth $31,000. Jane Street Group LLC grew its stake in shares of Maravai LifeSciences by 1,463.1% in the first quarter. Jane Street Group LLC now owns 380,403 shares of the company's stock valued at $841,000 after buying an additional 356,067 shares in the last quarter. Ascent Group LLC purchased a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $41,000. Finally, Clearline Capital LP raised its holdings in shares of Maravai LifeSciences by 9.6% in the 1st quarter. Clearline Capital LP now owns 205,339 shares of the company's stock valued at $454,000 after buying an additional 18,000 shares during the period. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

(Get Free Report)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Recommended Stories

Should You Invest $1,000 in Maravai LifeSciences Right Now?

Before you consider Maravai LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.

While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines